Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States
Christopher E. Bell(Abt Global (United States)), U Staginnus(Baxter (United States)), Chris L. Pashos(Oldham Council), Joel L. Weissfeld(University of Pittsburgh), Marc Botteman(Pharmerit (United States)), Darrell J. Triulzi(University of Pittsburgh), Xīn Gào(Qingdao University), Maarten J. Postma(University Medical Center Groningen)
Cited by 55
Related Papers
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet Neurology|2018|2.8k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
|Cochrane Database of Systematic Reviews|2016|1.2k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k